StocksInsight

MEDP Stock vs the S&P 500: Returns, Risk and Crash History

Medpace Holdings, Inc., healthcare (market value $18.6 billion): how it compared with the S&P 500, how it behaved in every crash since 2008, its risk‑adjusted returns and what analysts said. Returns to Oct 30, 2026; analyst data as of Nov 16, 2026.

Published Updated 4 min readHow we research

Key takeaways

  • MEDP returned +187.8% over the 5 years to Oct 30, 2026 versus +75.9% for the S&P 500: it beat the index.
  • Its 5-year Sharpe ratio was 0.62 against 0.58 for the S&P 500.
  • Its deepest crisis drawdown was −39.5% in the covid crash (feb–mar 2020) (S&P 500: −34.1%).
  • Five‑year volatility was 49.2% and beta 1.12.
  • 13 analysts rated it in the past year; 15% of their latest calls were Buy.
  • MEDP beat earnings estimates in 12 of its last 12 reports; the stock moved 16.1% on average, up or down, around each report.

What do the best‑ranked analysts on MEDP say now? See it in Exent Gems →

Did MEDP beat the S&P 500?

Over the 5 years to Oct 30, 2026, Medpace Holdings, Inc. (MEDP) returned +187.8% including dividends, versus +75.9% for the S&P 500 (SPY). It beat the index by 111.9 percentage points, or +23.5% a year against +12.0%.

PeriodMEDPS&P 500MEDP per yearS&P 500 per yearResult
1 year+11.5%+12.0%+11.5%+12.0%Lagged
3 years+168.7%+87.4%+39.0%+23.3%Beat
5 years+187.8%+75.9%+23.5%+12.0%Beat
10 years+2,147%+316.3%+36.5%+15.3%Beat
  • 1 year
    MEDP
    +11.5%
    S&P 500
    +12.0%
    MEDP per year
    +11.5%
    S&P 500 per year
    +12.0%
    Result
    Lagged
  • 3 years
    MEDP
    +168.7%
    S&P 500
    +87.4%
    MEDP per year
    +39.0%
    S&P 500 per year
    +23.3%
    Result
    Beat
  • 5 years
    MEDP
    +187.8%
    S&P 500
    +75.9%
    MEDP per year
    +23.5%
    S&P 500 per year
    +12.0%
    Result
    Beat
  • 10 years
    MEDP
    +2,147%
    S&P 500
    +316.3%
    MEDP per year
    +36.5%
    S&P 500 per year
    +15.3%
    Result
    Beat

Total return with dividends reinvested, from month-end prices to Oct 30, 2026. Beating the index on raw return is only half the story: the next section adjusts for the risk taken. See also how to beat the S&P 500.

What Wall Street analysts say about MEDP

In the 12 months to 30 days ago, 13 analysts published 92 ratings on MEDP. Their latest calls were 15% Buy, 85% Hold and 0% Sell. 5 of them rank 4★ or higher in Exent’s analyst scoring, which is based on each analyst’s past price‑target hit rate and returns.

The consensus 12‑month price target was $649.27 (range $515.00–$730.00), +0.4% from the last price. Remember that the average analyst’s target is hit only about half the time: how accurate are price targets?

Top‑ranked analyst coveringFirmStarsPrice‑target hit rate
Ann HynesMizuho Securities4.9★61.6%
David WindleyJefferies4.8★53.4%
Eric ColdwellRobert W. Baird4.7★54.8%
Jared HaaseWilliam Blair4.7★100.0%
Luke SergottBarclays4.7★67.7%

Ratings are shown with a 30‑day delay. Who the top‑ranked analysts on MEDP are, their live calls and the median target of only the top‑rated analysts are in Exent Gems.

The average analyst’s target is reached about 53.0% of the time; Exent Gems is built on the top 50 of Exent’s ranking,where some reached 90% or more over the last two years. Unlock the top 50 analysts.

MEDP returns by year vs the S&P 500

MEDP beat the S&P 500 in 7 of the 9 full calendar years shown.

YearMEDPS&P 500Difference
2026 (to Oct 30, 2026)+16.1%+11.7%+4.4%
2025+69.1%+17.7%+51.4%
2024+8.4%+24.9%−16.5%
2023+44.3%+26.2%+18.1%
2022−2.4%−18.2%+15.8%
2021+56.4%+28.7%+27.7%
2020+65.6%+18.3%+47.3%
2019+58.8%+31.2%+27.6%
2018+46.0%−4.6%+50.6%
2017+0.5%+21.7%−21.2%

MEDP risk-adjusted returns: Sharpe, Sortino and volatility

Over 5 years, MEDP had a Sharpe ratio of 0.62 against 0.58 for the S&P 500, so it earned more return per unit of risk than the index. Its annualized volatility was 41.8% and its beta 1.12: it tended to move about 1.1× as much as the market.

MetricMEDPS&P 500
Annual return+23.5%+12.0%
Volatility (annualized)41.8%15.5%
Sharpe ratio0.620.58
Sortino ratio1.150.91
Max drawdown (month-end)−41.0%−23.9%
Beta to the S&P 5001.121.00

Sharpe divides return above cash by total volatility; Sortino counts only downside volatility. Both use monthly returns and the 1–3 month T‑bill ETF (BIL) as the risk‑free rate.

How MEDP behaved in past crashes

MEDP’s deepest fall in the crises below was −39.5% in the covid crash (feb–mar 2020), against −34.1% for the S&P 500. The last column turns that into money: what a $100,000 position would have lost from peak to trough.

CrisisMEDPS&P 500Loss on $100,000
2018 trade-war selloff−26.1%−20.2%−$26,070
COVID crash (Feb–Mar 2020)−39.5%−34.1%−$39,470
2022 inflation bear market−39.3%−25.4%−$39,250
2025 tariff selloff−19.6%−19.0%−$19,610
WindowMEDP max drawdown
Last 1 year−36.6%
Last 3 years−39.4%
Last 5 years−42.9%
Last 10 years−42.9%

Peak‑to‑trough declines from daily prices inside each crisis window. A crash replay does not predict the next crisis; it shows how much room a holding needs. Run the same replay on a whole portfolio with the crash test.

What moves with MEDP, and what doesn’t

Correlation runs from −1 (moves opposite) to +1 (moves in lockstep). Over the last 60 months of monthly returns, MEDP’s correlation with the S&P 500 was 0.41, with the Nasdaq‑100 0.32, with long Treasuries (TLT) 0.07 and with gold (GLD) −0.18.

Adding a 5% MEDP position to an S&P 500 portfolio would have moved its 5‑year volatility from 15.5% to 15.7%.

Least correlated large capsCorrelationMost correlated large capsCorrelation
CME−0.10TMO0.52
PM−0.10EMR0.45
VZ−0.08JPM0.43
SO−0.08PH0.42
NEM−0.07IBKR0.42

Holdings that are highly correlated behave like one position in a selloff. See how to find hidden overlap.

Latest MEDP upgrades, downgrades and price‑target changes

DateRating and targetAnalyst
Oct 23Target raised
Buy
Target $730, was $700
Ann Hynes
Mizuho Securities
Oct 23Target raised
Buy
Target $699, was $624
Eric Coldwell
Robert W. Baird
Oct 23Target raised
Hold
Target $675, was $625
Luke Sergott
Barclays
Oct 7Target raised
Hold
Target $625, was $450
Luke Sergott
Barclays
Oct 7Target raised
Buy
Target $700, was $665
Ann Hynes
Mizuho Securities
Oct 2New coverage
Hold
Target $673
Kevin Caliendo
UBS
Sep 30New coverage
Hold
Target $673
Kevin Caliendo
UBS

Named analysts’ rating and price‑target changes on MEDP in the 5 weeks to Oct 20, 2026, shown 30 days after publication (the free analysts’ calls 3 days after). The top‑ranked analysts’ calls are in Exent Gems. See all of the latest analyst upgrades and downgrades.

Do analysts get MEDP right?

Of the 109 analyst price targets on MEDP set from 2019 until a year ago, 85.3% were reached within 12 months (data to Oct 20, 2026), 16.7 points above the 68.6% hit rate of the median stock in Exent’s study of 794 stocks. Targets that were reached took a median of 50 days. The median target sat 5.2% above the share price on the day it was set.

Where analysts said MEDP would be by now: a year ago, 6 analysts had a price target on MEDP, and the median of their latest targets was $577.50. On Oct 20, 2026 MEDP closed at $622.43, 7.8% above it.

85.3%of targets reached within 12 monthsMedian stock: 68.6%
50 daysmedian time to reach a target
+7.8%price now vs the median target set a year ago
AfterCallsMove on the call3 months vs S&P 500
Upgrades of MEDP8+4.0%−1.5%
Upgrades, all stocks11,514+2.5%+3.4%
Downgrades of MEDP13−1.3%+9.1%
Downgrades, all stocks10,700−3.0%−1.6%

The move on the call runs from the close before the rating change to the close after it; the last column is the stock’s return minus the S&P 500’s over the next three months. Averages of rating changes on MEDP through Sep 15, 2026; analysts are not named here. Do analyst upgrades move stocks?

How MEDP moves after earnings

MEDP beat the consensus earnings‑per‑share estimate in 12 of its last 12 quarterly reports, through the one on Jul 22, 2026, and the revenue estimate in 7 of 12. From the close before each report to the close after it, the stock moved 16.1% on average, up or down, against 6.8% for the average report across the 1,002 US stocks Exent tracks. It rose after 6 of the 12 reports. In 6 of the 12 beats the stock still fell.

12/12earnings beats
±16.1%average move per report
6/12reports followed by a rise
ReportEPS vs estimateRevenue vs estimateStock move
Jul 22, 2026$4.25 vs $3.98+2.6%+13.9%
Apr 22, 2026$4.28 vs $3.92+1.3%−23.6%
Feb 9, 2026$4.67 vs $4.19+2.8%−17.7%
Oct 22, 2025$3.86 vs $3.53+2.9%+9.3%
Jul 21, 2025$3.10 vs $2.98+12.0%+53.2%
Apr 21, 2025$3.67 vs $3.06+6.1%−4.7%
Feb 10, 2025$3.67 vs $2.96−0.6%−7.4%
Oct 21, 2024$3.01 vs $2.78−0.3%−8.4%

Reported earnings per share against the consensus estimate, revenue surprise in percent, and the stock’s price change over the two sessions around the report. How stocks move after earnings

Where MEDP’s revenue comes from

In fiscal 2025, MEDP’s largest segment was Oncology, with 29.5% of $2.5 billion revenue (+14.8% on the year before).

SegmentRevenueShareGrowth
Oncology$747.6 million29.5%+14.8%
Metabolic$745.0 million29.4%+62.8%
Other$408.5 million16.1%−5.3%
Central Nervous System$254.8 million10.1%+40.0%
Cardiology$239.4 million9.5%+3.9%
Antiviral And Anti Infective$134.9 million5.3%−13.8%

From MEDP’s annual filings; segment growth compares fiscal 2025 with the year before. Regions are as each company reports them, so one company’s “Asia Pacific” is not another’s. China counts the regions a company reports as China, Greater China or Hong Kong; a separately reported Taiwan is not counted. Which S&P 500 companies depend most on China?

Members of Congress who traded MEDP

As of Oct 20, 2026, 6 members of Congress had disclosed 21 trades in MEDP (9 buys and 12 sales) in STOCK Act disclosures filed with the House and Senate. The latest public trade is dated May 15, 2026.

Trade dateMemberTypeAmount
May 15, 2026David TaylorBuy$1,001–$15,000
Feb 26, 2026David TaylorBuy$1,001–$15,000
Jan 29, 2026David TaylorBuy$1,001–$15,000
Jan 16, 2026David TaylorSale$1,001–$15,000
Jan 15, 2026Gilbert CisnerosSale$15,001–$50,000
Oct 9, 2025Gilbert CisnerosSale$1,001–$15,000
Aug 4, 2025Lisa McClainSale$1,001–$15,000
Jul 24, 2025Gilbert CisnerosSale$1,001–$15,000
Jul 23, 2025David TaylorSale$1,001–$15,000
Jul 22, 2025Lisa McClainBuy$1,001–$15,000

Amounts are the ranges members report, not exact values. The STOCK Act gives members up to 45 days to disclose a trade, so trades appear weeks after they are made. See every member’s disclosed trades

Are MEDP insiders buying or selling?

In the 12 months to Oct 20, 2026, MEDP insiders made no open‑market purchases and 33 sales worth $108.6 million, according to SEC Form 4 filings. The last open‑market purchase on record was on Feb 27, 2025.

After the 38 insider purchases of $10,000 or more since 2012, MEDP beat the S&P 500 by an average of 48.9 percentage points over the next 12 months; 90% of them were followed by a beat. Across all 17,865 insider purchases in Exent’s study, the average was +17.2% and the median +1.0% against the index.

Q1 ’25
Q2 ’25
Q3 ’25
Q4 ’25
Q1 ’26
Q2 ’26
Q3 ’26
Q4 ’26
DateInsiderRoleValue
Feb 27, 2025Ewald Stephen PGeneral Counsel & Corp. Secy.$652
Sep 22, 2022Medpace Investors, LLC10 percent owner$8.9 million
Sep 22, 2022Troendle August J.Director, 10 percent owner, officer: CEO$8.9 million
Sep 21, 2022Troendle August J.Director, 10 percent owner, officer: CEO$15.2 million
Sep 21, 2022Medpace Investors, LLC10 percent owner$15.2 million

The table lists the latest open‑market purchases on record, leaving out the last 30 days. The chart counts Form 4 purchases and sales by calendar quarter. Purchases are open‑market buys; sales include planned sales under 10b5‑1 trading plans. Do insider buys beat the market?

How much of MEDP is sold short?

As of the Sep 30, 2026 settlement date, 7.05% of MEDP’s float was sold short: 1.6 million shares, or 5.8 days of average trading volume to cover. A year earlier (Oct 15, 2025) it was 7.40%. The median across the 997 US stocks Exent tracks was 4.77%, so MEDP is more heavily shorted than most.

  • Apr 30, 20266.85%
  • May 29, 20269.07%
  • Jun 30, 20269.38%
  • Jul 31, 20267.71%
  • Aug 31, 20267.37%
  • Sep 30, 20267.05%

From FINRA short‑interest reports, filed twice a month; the bars show the short share of the float at each month‑end. Days to cover divides the shares short by the average daily volume. The most shorted stocks

How many institutions own MEDP?

At the end of Q2 2026 (Jun 30, 2026), 713 institutions reported holding MEDP in 13F filings, down 30 from the quarter before and up from 616 a year earlier. Their reported holdings add up to 88.6% of MEDP’s shares. In the quarter 289 institutions added to their positions and 307 cut them.

71313F holders
78new positions
107positions closed
88.6%of shares held by 13F filers

Investment managers with over $100 million in US equities file 13F reports within 45 days of each quarter end, so this is the latest complete quarter. Holdings can add up to more than 100% when shares are lent and counted twice. Which stocks institutions are buying and selling

Is MEDP diluting shareholders?

MEDP’s diluted share count fell 21.7% over the five fiscal years to fiscal 2025 and fell 7.8% in fiscal 2025 alone. Each share now owns a larger slice of the company. The median change across the 1,005 US stocks Exent tracks was −0.1%.

Stock‑based compensation was $34.8 million in fiscal 2025, 1.4% of revenue. MEDP spent $917.4 million buying back shares, a buyback yield of 5.47% of its market value; stock pay equaled 3.8% of the buybacks.

−7.8%share count, 1 year
−21.7%share count, 5 years
1.4%stock pay as % of revenue
5.47%buyback yield

Weighted‑average diluted shares from MEDP’s annual income statements; stock‑based compensation and buybacks from its cash‑flow statement. Stock dilution and stock‑based compensation, explained

MEDP financial health scores

In Exent’s Oct 20, 2026 snapshot, MEDP’s Altman Z‑score was 8.14, in the safe zone (where 465 of the 794 non‑financial US stocks Exent tracks sit). Its Piotroski F‑score was 7 out of 9; 40% of scored stocks reach 7 or more.

8.14Altman Z‑score: safe zone
7/9Piotroski F‑score

The Altman Z‑score combines five balance‑sheet and earnings ratios into one bankruptcy‑risk score: below 1.81 is the distress zone, 1.81–2.99 grey, above 2.99 safe. It is not meaningful for banks, insurers and REITs. The Piotroski F‑score counts nine yes/no tests of profitability, leverage and efficiency; 8–9 is strong, 0–2 weak. Both come from the latest annual statements. Which stocks have the highest bankruptcy risk?

Which ETFs hold MEDP?

As of Oct 20, 2026, 32 of the 304 ETFs Exent tracks held MEDP. Its largest weight is in FXH (First Trust Health Care AlphaDEX Fund), at 2.33% of the fund.

ETFFundWeight of MEDP
FXHFirst Trust Health Care AlphaDEX Fund2.33%
FTXHFirst Trust Nasdaq Pharmaceuticals ETF1.52%
IJKiShares S&P Mid-Cap 400 Growth ETF0.70%
IJHiShares Core S&P Mid-Cap ETF0.42%
IWPiShares Russell Mid-Cap Growth ETF0.42%
SPMDState Street SPDR Portfolio S&P 400 Mid Cap ETF0.41%
MDYState Street SPDR S&P MIDCAP 400 ETF Trust0.41%
VBKVanguard Small-Cap Growth Index Fund ETF Shares0.40%

Owning several of these funds stacks the same position. How much do VOO, QQQ and VTI overlap?

The right benchmark for MEDP

Exent matches every holding to the index with the most similar risk. For MEDP that is MDY. Comparing a holding with an index that carries very different risk makes good results look bad and risky ones look clever. Read why the S&P 500 is the wrong benchmark for most portfolios.

Other healthcare stocks

TickerName5‑year returnVolatility (5y)
LLYEli Lilly and Company+482.3%32.6%
JNJJohnson & Johnson+92.9%16.8%
ABBVAbbVie Inc.+207.1%23.5%
ZBHZimmer Biomet Holdings, Inc.−28.8%26.9%
ALNYAlnylam Pharmaceuticals, Inc.+3.4%50.5%
RVTYRevvity, Inc.−10.2%33.9%
THCTenet Healthcare Corporation+281.3%45.0%
EXELExelixis, Inc.+222.6%35.4%

Data and methodology

Returns are total returns from month‑end adjusted closing prices (dividends reinvested) through Oct 30, 2026. Crisis drawdowns and trailing maximum drawdowns use daily prices. Analyst coverage counts ratings published in the last 12 months, shown with a 30‑day delay. Full method: Exent methodology.

Company data as of Oct 20, 2026. The move around an earnings report runs from the close before it to the close after it; a price target counts as hit when the stock closed at or beyond it within 12 months (Exent analyst data). Revenue by region and segment, share counts and executive pay come from company filings; insider trades from SEC Form 4, short interest from FINRA, institutional ownership from 13F filings, Congress trades from STOCK Act disclosures filed with the House and Senate, federal contracts from USAspending.gov. Filings from the last 30 days are shown as counts only.

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Check MEDP with Exent Gems

Wall Street’s average MEDP price target is in line with the latest share price. See what the best‑ranked analysts on MEDP say now in Exent Gems.

  1. Exent ranks Wall Street analysts by their past price‑target hit rate and returns, and keeps the best‑ranked few.
  2. Gems shows who the top‑ranked analysts covering MEDP are, their live calls and the median target of only the top‑rated analysts.
  3. Gems flags the stocks where several top‑ranked analysts agree: a starting point for your own research, not a promise.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

Yes. MEDP returned +2,147% (+36.5% a year) over the 10 years to Oct 30, 2026, versus +316.3% (+15.3% a year) for the S&P 500, including dividends.

No. As of Oct 20, 2026, MEDP (Medpace Holdings, Inc.) is not one of the 503 stocks in the S&P 500.

No. As of Oct 20, 2026, MEDP (Medpace Holdings, Inc.) is not one of the 101 stocks in the Nasdaq-100.

MEDP fell −39.5% from peak to trough during the covid crash (feb–mar 2020), versus −34.1% for the S&P 500.

MEDP fell −39.3% from peak to trough during the 2022 inflation bear market, versus −25.4% for the S&P 500.

Over the 5 years to Oct 30, 2026, MEDP’s Sharpe ratio was 0.62 and its Sortino ratio 1.15, versus 0.58 and 0.91 for the S&P 500.

MEDP’s 5‑year annualized volatility was 49.2%, higher than the S&P 500’s 17.0%, with a beta of 1.12.

Among large US stocks, the lowest correlations with MEDP over the last 60 months were CME (−0.10), PM (−0.10), VZ (−0.08). Its correlation with long Treasuries (TLT) was 0.07 and with gold (GLD) −0.18.

MEDP beat the consensus earnings-per-share estimate in 12 of its last 12 quarterly reports through Jul 22, 2026, and the revenue estimate in 7 of 12. The stock moved 16.1% on average, up or down, from the close before each report to the close after it.

Yes. As of Oct 20, 2026, 6 members of Congress had disclosed 21 trades in MEDP (9 buys and 12 sales) in STOCK Act disclosures filed with the House and Senate.

As of the Sep 30, 2026 settlement date, 7.05% of MEDP’s float was sold short (1.6 million shares, 5.8 days to cover), according to FINRA short-interest reports. A year earlier it was 7.40%.

No. MEDP’s diluted share count fell 21.7% over the five fiscal years to fiscal 2025 and fell 7.8% in the latest year. Stock-based compensation was 1.4% of revenue, and buybacks totaled $917.4 million.

What do the best‑ranked analysts say on MEDP now?

Exent ranks Wall Street analysts by their track record. Gems shows who the top‑ranked analysts on MEDP are, their latest calls and the stocks where several of them agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.